Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.
Sex hormonal milieus during the female fertility cycle modulate the tumor vascular permeability of breast cancer. It has been proposed that the liposomal formulated doxorubicin (ie, Doxil), given at the menstrual/estrous stage with the predicted highest tumor vascular permeability, allows significantly increased drug retention in the breast tumor. In the current study, syngeneic murine 4T1 mammary tumors were established on the backs of female BALB/c mice and Doxil was administered at particular mouse estrous cycle stages. The results indicated that Doxil administration during certain times in the mouse estrous cycle was crucial for drug retention in 4T1 tumor tissues. Significantly higher drug concentrations were detected in the tumor tissues when Doxil was administered during the diestrus stage, as compared to when the drug injection was given at all other estrous stages. Our study also showed that the tumor-bearing mice exhibited nearly normal rhythmicity of the estrous cycle post drug injection, indicating the feasibility of continual injection of Doxil at the same estrous cycle stage. By using 4T1 cells cultured in vitro, we showed that progesterone (P4) significantly inhibited cell proliferation and the production of six tumor-derived cytokines, eg, sTNF-RI, CXCL-16, GM-CSF, MIP-1alpha, MIP-1gamma, and Flt3-L. Some of these factors have been shown to be vascular modulators in diverse tissues. In this report, we demonstrated that the concentration of P4 in the plasma and/or estrous cycle stage of 4T1 tumor-bearing mice can be used to select the best time for administrating the liposomal anticancer drugs.
You
Shaojin
S
Experimental Cancer Therapeutic Laboratory and Histopathology Core, Atlanta Research and Educational Foundation (151F), Atlanta VA Medical Center, Decatur, GA, USA. shaojin.you@va.gov
Zuo
Lian
L
Li
Wei
W
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D015552:Injections, Intralesional / Q000379:methods; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin
Int J Cancer. 2001 Aug 15;93(4):590-600
11477565
Oncologist. 2003;8 Suppl 2:3-9
13679590
Br J Cancer. 1999 Dec;81(8):1311-7
10604727
Mol Pharmacol. 1992 Jun;41(6):993-8
1614415
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
2946403
In Vitro Cell Dev Biol Anim. 2004 Jul-Aug;40(7):187-95
15161341
Int Immunol. 2007 Sep;19(9):1095-102
17855433
Life Sci. 2002 Dec 27;72(6):677-87
12467908
Biochem Biophys Res Commun. 1986 Apr 29;136(2):521-8
3010982
Biochim Biophys Acta. 2003 Jan 10;1609(1):102-8
12507764
Cancer Lett. 1997 Oct 28;119(1):79-85
18372525
Life Sci. 2001 Dec 21;70(5):591-601
11811903
Int J Cancer. 2002 Oct 10;101(5):415-22
12216068
Int J Exp Pathol. 2007 Oct;88(5):351-60
17877537
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3919-24
19237581
Cancer Res. 1998 Jan 1;58(1):159-65
9426072
NCI Monogr. 1986;(1):105-9
3534581
Mol Cancer Ther. 2005 Jul;4(7):1065-75
16020664
Biochemistry. 1987 Jun 30;26(13):3776-81
2820475
Med Hypotheses. 2008;71(1):141-7
18299174
Proc Soc Exp Biol Med. 1976 Nov;153(2):254-7
1033549
Eur J Cancer. 2003 Aug;39(12):1668-75
12888360
Drugs. 1997;54 Suppl 4:22-9
9361958
J Pharmacol Exp Ther. 2001 Nov;299(2):775-81
11602694
Endocrinology. 1992 Apr;130(4):1923-30
1547720
Am J Respir Cell Mol Biol. 1997 Jul;17(1):70-7
9224211